A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Public ClinicalTrials.gov record NCT01511913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting
Study identification
- NCT ID
- NCT01511913
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,411 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2012
- Primary completion
- Mar 29, 2018
- Completion
- Dec 11, 2019
- Last update posted
- Dec 27, 2021
2012 – 2019
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Gilbert | Arizona | 85234 | — |
| Local Institution | Hot Springs | Arkansas | 71913 | — |
| Local Institution | Encinitas | California | 92024 | — |
| Local Institution | La Jolla | California | 92093 | — |
| Local Institution | Long Beach | California | 90813 | — |
| Local Institution | Los Angeles | California | 90025 | — |
| Local Institution | Denver | Colorado | 80218 | — |
| Local Institution | Washington D.C. | District of Columbia | 20010 | — |
| Local Institution | Lakeland | Florida | 33085 | — |
| Local Institution | Miami Beach | Florida | 33140 | — |
| Local Institution | Orange Park | Florida | 32073 | — |
| Local Institution | Chicago | Illinois | 60612 | — |
| Local Institution | Niles | Illinois | 60714 | — |
| Local Institution | Detroit | Michigan | 48201 | — |
| Local Institution | Hattiesburg | Mississippi | 39401 | — |
| Local Institution | Lincoln | Nebraska | 18015 | — |
| Local Institution | Morristown | New Jersey | 07960 | — |
| Local Institution | Canton | Ohio | 44178 | — |
| Mid Ohio Onc/Hem, Inc | Columbus | Ohio | 43206 | — |
| Local Institution | Columbus | Ohio | 43219 | — |
| Local Institution | Middletown | Ohio | 45042 | — |
| Local Institution | Portland | Oregon | 97213 | — |
| Local Institution | Knoxville | Tennessee | 37920 | — |
| Local Institution | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 162 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01511913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2021 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01511913 live on ClinicalTrials.gov.